Reuters -- A new influenza drug, which has been billed as a possible weapon against both H1N1 swine flu and H5N1 bird flu, has succeeded in late-stage trials in Asia, its discoverer, Australian biotech firm Biota (BTA.AX), said on Monday.
Reuters -- A new influenza drug, which has been billed as a possible weapon against both H1N1 swine flu and H5N1 bird flu, has succeeded in late-stage trials in Asia, its discoverer, Australian biotech firm Biota (BTA.AX), said on Monday.
